FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947183763> ?p ?o ?g. }

• W2947183763 abstract "There is limited information available regarding the clinical management of intravenous immunoglobulin-resistant Kawasaki disease (KD). We aimed to evaluate the optimal treatment options for patients with refractory KD by presenting an indirect-comparison meta-analysis. PubMed, EMBASE, Web of Science, and the Cochrane Database were searched on August 31, 2018. Unpublished studies were also searched in ProQuest Dissertations & Theses and through manual retrieval strategies. Randomized concurrent controlled trials (RCTs), high-quality non-randomized concurrent controlled trials (non-RCTs), and retrospective studies associated with AEs were included. The quality of all eligible studies was assessed using Cochrane collaboration’s tool and non-randomized study guidelines. Risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes were estimated in our analysis. GRADE profiler 3.6.1 was used to assess the evidence profile. Twelve studies involving 372 immunoglobulin-resistant KD patients were identified and analyzed. Neither infliximab nor intravenous pulse methylprednisolone (IVMP) was significantly more effective than second IVIG infusion with respect to lowering coronary artery lesions (CALs) (infliximab, 0.85, 0.43–1.69; IVMP, 0.99, 0.52–1.88) and treatment resistance (infliximab, 0.43, 0.21–0.89; IVMP, 1.16, 0.33–4.13). No significant differences were found between infliximab and IVMP in the incidence rate of CALs (0.70, 0.27–1.81), the treatment resistance (0.37, 0.09–1.60), the rates of coronary artery aneurysm (4.13, 0.38–45.22) and the coronary artery dilatation (0.45, 0.10–1.99). Furthermore, compared with second IVIG infusion, both infliximab and IVMP showed significant effectiveness in antipyretic effects (infliximab, 1.52, 1.16–1.99; IVMP, 1.29, 0.77–2.15). However, Infliximab was noninferior to IVMP on antipyretic effects (1.18, 0.66–2.15). IVMP treatment showed significant association with fewer AEs than second IVIG infusion (0.49, 0.26–0.94) and infliximab (2.34, 1.07–5.09). No significant differences were noted between infliximab treatment and second IVIG infusion (1.06, 0.69–1.63). Infliximab, IVMP, and second IVIG infusion showed no significant differences in the cardioprotective effect or the rate of treatment resistance. Infliximab and IVMP treatment were more effective than second IVIG infusion regarding antipyretic effects. IVMP treatment may have an advantage due to its lower total rate of AEs associated with drug infusion. The study has been registered on PROSPERO ( CRD42016039693 )." @default.
• W2947183763 created "2019-06-07" @default.
• W2947183763 creator A5025204831 @default.
• W2947183763 creator A5025541994 @default.
• W2947183763 creator A5033960263 @default.
• W2947183763 creator A5035591571 @default.
• W2947183763 creator A5053514193 @default.
• W2947183763 creator A5070295178 @default.
• W2947183763 creator A5089124196 @default.
• W2947183763 date "2019-05-17" @default.
• W2947183763 modified "2023-10-16" @default.
• W2947183763 title "Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease" @default.
• W2947183763 cites W1963598954 @default.
• W2947183763 cites W1964515379 @default.
• W2947183763 cites W1972002164 @default.
• W2947183763 cites W1976197580 @default.
• W2947183763 cites W1985738971 @default.
• W2947183763 cites W2007872832 @default.
• W2947183763 cites W2010666563 @default.
• W2947183763 cites W2015774710 @default.
• W2947183763 cites W2017044005 @default.
• W2947183763 cites W2032095501 @default.
• W2947183763 cites W2047539120 @default.
• W2947183763 cites W2049199673 @default.
• W2947183763 cites W2050966310 @default.
• W2947183763 cites W2065307756 @default.
• W2947183763 cites W2079271582 @default.
• W2947183763 cites W2104971423 @default.
• W2947183763 cites W2108558922 @default.
• W2947183763 cites W2109450728 @default.
• W2947183763 cites W2116475791 @default.
• W2947183763 cites W2118546214 @default.
• W2947183763 cites W2119962795 @default.
• W2947183763 cites W2127586127 @default.
• W2947183763 cites W2134243096 @default.
• W2947183763 cites W2136400660 @default.
• W2947183763 cites W2136403658 @default.
• W2947183763 cites W2140983900 @default.
• W2947183763 cites W2144879085 @default.
• W2947183763 cites W2152621561 @default.
• W2947183763 cites W2156098321 @default.
• W2947183763 cites W2212818630 @default.
• W2947183763 cites W2253607857 @default.
• W2947183763 cites W2314093230 @default.
• W2947183763 cites W2514411981 @default.
• W2947183763 cites W2535524641 @default.
• W2947183763 cites W2565659334 @default.
• W2947183763 cites W2589994269 @default.
• W2947183763 cites W2601489012 @default.
• W2947183763 cites W2604027935 @default.
• W2947183763 cites W2731552962 @default.
• W2947183763 cites W2738278522 @default.
• W2947183763 cites W2744586321 @default.
• W2947183763 cites W2769565503 @default.
• W2947183763 cites W2769735587 @default.
• W2947183763 cites W2773735506 @default.
• W2947183763 cites W2805052095 @default.
• W2947183763 cites W2991792334 @default.
• W2947183763 cites W4211236826 @default.
• W2947183763 cites W4234779229 @default.
• W2947183763 cites W4255017270 @default.
• W2947183763 doi "https://doi.org/10.1186/s12887-019-1504-9" @default.
• W2947183763 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6524334" @default.
• W2947183763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31101091" @default.
• W2947183763 hasPublicationYear "2019" @default.
• W2947183763 type Work @default.
• W2947183763 sameAs 2947183763 @default.
• W2947183763 citedByCount "17" @default.
• W2947183763 countsByYear W29471837632019 @default.
• W2947183763 countsByYear W29471837632020 @default.
• W2947183763 countsByYear W29471837632021 @default.
• W2947183763 countsByYear W29471837632022 @default.
• W2947183763 countsByYear W29471837632023 @default.
• W2947183763 crossrefType "journal-article" @default.
• W2947183763 hasAuthorship W2947183763A5025204831 @default.
• W2947183763 hasAuthorship W2947183763A5025541994 @default.
• W2947183763 hasAuthorship W2947183763A5033960263 @default.
• W2947183763 hasAuthorship W2947183763A5035591571 @default.
• W2947183763 hasAuthorship W2947183763A5053514193 @default.
• W2947183763 hasAuthorship W2947183763A5070295178 @default.
• W2947183763 hasAuthorship W2947183763A5089124196 @default.
• W2947183763 hasBestOaLocation W29471837631 @default.
• W2947183763 hasConcept C126322002 @default.
• W2947183763 hasConcept C168563851 @default.
• W2947183763 hasConcept C197934379 @default.
• W2947183763 hasConcept C2776478404 @default.
• W2947183763 hasConcept C2776820930 @default.
• W2947183763 hasConcept C2777138892 @default.
• W2947183763 hasConcept C2778213512 @default.
• W2947183763 hasConcept C2779134260 @default.
• W2947183763 hasConcept C2781423770 @default.
• W2947183763 hasConcept C71924100 @default.
• W2947183763 hasConcept C95190672 @default.
• W2947183763 hasConceptScore W2947183763C126322002 @default.
• W2947183763 hasConceptScore W2947183763C168563851 @default.
• W2947183763 hasConceptScore W2947183763C197934379 @default.
• W2947183763 hasConceptScore W2947183763C2776478404 @default.
• W2947183763 hasConceptScore W2947183763C2776820930 @default.
• W2947183763 hasConceptScore W2947183763C2777138892 @default.
• W2947183763 hasConceptScore W2947183763C2778213512 @default.

• next